PMAM
APLS

Picton Mahoney Asset Management’s Apellis Pharmaceuticals APLS Stock Holding History

Picton Mahoney Asset Management’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-52,500
Closed -$3.15M – 388
2023
Q4 		$3.15M Sell
52,500
-70,000
-57% -$3.55M 0.09% 167
2023
Q3 		$4.66M Buy
+122,500
New +$5.38M 0.14% 149

Other funds holding APLS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Picton Mahoney Asset Management's APLS Position: Q1 2026 in Review

Picton Mahoney Asset Management opened a new position in Apellis Pharmaceuticals (APLS) in Q1 2026: 150,000 shares worth $6.03M. The stake represents 0.04% of the portfolio and ranks #328 among its holdings. This is a return to the name: Picton Mahoney Asset Management previously reported a position in APLS as recently as Q4 2023.

Picton Mahoney Asset Management first reported a position in APLS in Q3 2022 and has held it in 7 quarters since. 321 funds tracked by Wall St. Rank hold APLS as of Q1 2026.

  • Picton Mahoney Asset Management held 150,000 shares of Apellis Pharmaceuticals worth $6.03M as of Q1 2026.
  • Apellis Pharmaceuticals was a new Picton Mahoney Asset Management position in Q1 2026.
  • Apellis Pharmaceuticals made up 0.04% of Picton Mahoney Asset Management's portfolio in Q1 2026, its #328 holding.
  • Picton Mahoney Asset Management first reported a position in Apellis Pharmaceuticals in Q3 2022 and has held it in 7 quarters since.
  • 321 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q1 2026.

Based on Picton Mahoney Asset Management's 13F filing for Q1 2026, filed 13 May 2026.